Plasminogen in proliferative vitreoretinal disorders

British Journal of Ophthalmology

Volumn 81, Issue 7, 1997, Pages 590-594

  Esser, Peter ^a   Heimann, Klaus ^a   Bartz Schmidt, Karl Ulrich ^a   Walter, Peter ^a   Krott, Ralf ^a   Weller, Michael ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VITRECTOMY; VITREORETINOPATHY;

EID: 0030860913     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.81.7.590     Document Type: Article

References (43)

1. Jaffe GJ, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology 1990;97:184-9.
2. Boldt HC, Abrams GW, Murray TG, Han DP, Mieler WF. The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin. Retina 1992;12:75-9.
3. Williams DF, Bennett SR, Abrams GW, Han DP, Mieler WF, Jaffe GJ, et al. Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. Am J Ophthalmol 1990;109:606-7.
4. Jaffe GJ, Lewis H, Han DP, Williams GA, Abrams GW. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Am J Ophthalmol 1989;108: 170-5.
5. Dabbs CK, Aaberg TM, Aguilar HE, Sternberg P, Jr, Meredith TA, Ward AR Complications of tissue plasminogen activator therapy after vitrectomy for diabetes. Am J Ophthalmol 1990;110:354-60.
6. Koutsandrea C, Apostolopoulus M, Theodossiadis P. The use of tissue plasminogen activator in postvitrectomy cases. Int Ophthalmol 1993;17:95-100.
7. Lambrou FH, Snyder RW, Williams GA, Lewandowski M. Treatment of experimental intravitreal fibrin with tissue plasminogen activator. Am J Ophthalmol 1987;104:619-23.
8. Koerner F, Boehnke M. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis. Ger J Ophthalmol 1992;1:354-60.
9. Baziuk N, Fang T, Peyman GA, Gremillion CM, Jr. Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis. Int Ophthalmol 1991;15:79-86.
10. Johnson RN, Olsen KR, Hernandez E. Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage. Arch Ophthalmol 1989;107:891-4.
11. Lewis H, Resnick SC, Flannery JG, Straatsma BR. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991;111:197-204.
12. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Retina 1991;11:250-8.
13. Vander JF. Tissue plasminogen activator irrigation to facilitate removal of subretinal hemorrhage during vitrectomy. Ophthalmic Surg 1992;23:361-3.
14. Peyman GA, Nelson NC, Jr., Alturki W, Blinder KJ, Paris CL, Desai UR, et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 1991;22:575-82.
15. Miyashita C, Wenzel E, Heiden M. Plasminogen: a brief introduction into its biochemistry and function. Haemostasis 1988;18:7-13.
16. Immonen IJ, Salonen EM, Vaheri AI, Laatikainen LT. Plasmin in subretinal fluid. Acta Ophthalmol 1988;66:647-51.
17. Weller M, Esser P, Bresgen M, Heimann K, Wiedemann P. Thrombospondin:a new attachment protein in preretinal traction membranes. Eur J Ophthalmol 1992;2:10-4.
18. Friberger P, Knös M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978;7:138-15.
19. Vinazzer H. Basics and practice in evaluating plasminogen. Haemostasis 1988;18:41-5.
20. Lowry OH, Rosebrough BJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
21. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy:differentiation of subpopulations. Br J Ophthalmol 1993;77:731-3.
22. Esser P, Bresgen M, Weller M, Heimann K, Wiedemann P. The significance of vitronectin in proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1994;232: 477-81.
23. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990;23:197-211.
24. Wun TC. Plasminogen activation: biochemistry, physiology and therapeutics. Crit Rev Biotechnol 1988;8:131-48.
25. Weller M, Wiedemann P, Heimann K. Proliferarive vitreoretinopathy - is it anything more than wound healing at the wrong place? Int Ophthalmol 1990;14:105-17.
26. Weller M, Wiedemann P, Bresgen M, Heimann K. Giant preretinal membrane formation behind a silicone oil bubble in a hypotensive eye. Retina 1990;10:86-91.
27. Weller M, Bresgen M, Heimann K, Wiedemann P. Blood coagulation factor XIII contributes to the development of traction retinal detachment. Acta Ophthalmol 1990;68:246-52.
28. Weller M, Wiedemann P, Heimann K, Zilles K. The significance of fibronectin in vitreoretinal pathology. A critical evaluation. Graefes Arch Clin Exp Ophthalmol 1988;226: 294-8.
29. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993;111:849-54.
30. Toth CA, Morse LS, Hjelmeland LM, Landers MB, 3d. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991;109:723-9.
31. Brignole F, Baudouin C, Roul C, Gastaud P, Bayle J. Tissue-type plasminogen activator (TPA) and plasminogen activator inhibitor (PAI) in serum, vitreous and subretinal fluid from patients with proliferative vitreoretinopathy (ARVO abstract). Invest Ophthalmol Vis Sci 1994;35:2041.
32. Tripathi BJ, Park JK, Tripathi RC. Extracellular release of tissue plasminogen activator is increased with the phagocytic activity of the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1989;30:2470-3.
33. Machemer R, Laqua H. Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol 1975;80:1-23.
34. Siren V, Stephens RW, Salonen EM, Vaheri A, Summanen P, Immonen I. Retinal pigment epithelial cells secrete urokinase-type plasminogen activator and its inhibitor PAI-1. Ophthalmic Res 1992;24:203-12.
35. Cederholm-Williams SA, Dornan TL, Turner RC. Abnormal release of vascular plasminogen activator associated with diabetic microangiopathy. In: Jespersen J, Kluft C, Korsgaard O, eds. Clinical aspects of fibrinolysis and thrombolysis. Esbjerg, Denmark: South Jutland University Press, 1983:322-35.
36. Lutty GA, Ikeda K, Chandler C, McLeod DS. Immunolocalization of tissue plasminogen activator in the diabetic and nondiabetic retina and choroid. Invest Ophthalmol Vis Sci 1991;32:237-45.
37. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus. J Clin Invest 1979;63:485-93.
38. Christe M, Fritsche J, Lämmle B, Tran TH, Marbet GA, Berger W, et al. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemostas 1984;52:138-43.
39. Landgraf-Leurs MMC, Ladik T, Smolka B, Bock T, Schramm W, Spannagl M, et al. Increased thromboplastic potential in diabetes:a multifactorial phenomenon. Klin Wochenschr 1987;65:600-6.
40. Weller M, Wiedemann P, Bresgen M, Heimann K. Vitronectin and proliferadve intraocular disorders. I A colocalisation study of the serum spreading factor, vitronectin, and fibronectin in traction membranes from patients with proliferative vitreoretinopathy. Int Ophthalmol 1991;15:93-101.
41. Preissner KT, Müller-Berghaus G. S-Protein modulates the heparin catalyzed inhibition of thrombin by anti-thrombin III. Eur J Biochem 1986;156:645-50.
42. Preissner KT, Holzhüter S, Justus C, Müller-Berghaus G. Identification and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989;74: 1989-96.
43. Seiffert D, Mimuro J, Schleef RR, Loskutoff DJ. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin. Cell Differ Dev 1990;32:287-92.